Connection
Robert Freedman to Antipsychotic Agents
This is a "connection" page, showing publications Robert Freedman has written about Antipsychotic Agents.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
1.763 |
|
|
|
-
Kem WR, Olincy A, Johnson L, Harris J, Wagner BD, Buchanan RW, Christians U, Freedman R. Pharmacokinetic Limitations on Effects of an Alpha7-Nicotinic Receptor Agonist in Schizophrenia: Randomized Trial with an Extended-Release Formulation. Neuropsychopharmacology. 2018 02; 43(3):583-589.
Score: 0.451
-
Freedman R, Carpenter WT, Davis JM, Goldman HH, Tamminga CA, Thomas M. The costs of drugs for schizophrenia. Am J Psychiatry. 2006 Dec; 163(12):2029-31.
Score: 0.214
-
Freedman R. The choice of antipsychotic drugs for schizophrenia. N Engl J Med. 2005 Sep 22; 353(12):1286-8.
Score: 0.197
-
Adler LE, Olincy A, Cawthra EM, McRae KA, Harris JG, Nagamoto HT, Waldo MC, Hall MH, Bowles A, Woodward L, Ross RG, Freedman R. Varied effects of atypical neuroleptics on P50 auditory gating in schizophrenia patients. Am J Psychiatry. 2004 Oct; 161(10):1822-8.
Score: 0.184
-
Freedman R. Schizophrenia. N Engl J Med. 2003 Oct 30; 349(18):1738-49.
Score: 0.173
-
Simosky JK, Stevens KE, Adler LE, Freedman R. Clozapine improves deficient inhibitory auditory processing in DBA/2 mice, via a nicotinic cholinergic mechanism. Psychopharmacology (Berl). 2003 Feb; 165(4):386-96.
Score: 0.162
-
Kantrowitz JT, Javitt DC, Freedman R, Sehatpour P, Kegeles LS, Carlson M, Sobeih T, Wall MM, Choo TH, Vail B, Grinband J, Lieberman JA. Double blind, two dose, randomized, placebo-controlled, cross-over clinical trial of the positive allosteric modulator at the alpha7 nicotinic cholinergic receptor AVL-3288 in schizophrenia patients. Neuropsychopharmacology. 2020 07; 45(8):1339-1345.
Score: 0.134
-
Simosky JK, Freedman R, Stevens KE. Olanzapine improves deficient sensory inhibition in DBA/2 mice. Brain Res. 2008 Oct 03; 1233:129-36.
Score: 0.060
-
Buchanan RW, Freedman R, Javitt DC, Abi-Dargham A, Lieberman JA. Recent advances in the development of novel pharmacological agents for the treatment of cognitive impairments in schizophrenia. Schizophr Bull. 2007 Sep; 33(5):1120-30.
Score: 0.056
-
Martin LF, Kem WR, Freedman R. Alpha-7 nicotinic receptor agonists: potential new candidates for the treatment of schizophrenia. Psychopharmacology (Berl). 2004 Jun; 174(1):54-64.
Score: 0.044
-
Leonard S, Adams C, Breese CR, Adler LE, Bickford P, Byerley W, Coon H, Griffith JM, Miller C, Myles-Worsley M, Nagamoto HT, Rollins Y, Stevens KE, Waldo M, Freedman R. Nicotinic receptor function in schizophrenia. Schizophr Bull. 1996; 22(3):431-45.
Score: 0.025
-
Freedman R, Adler LE, Bickford P, Byerley W, Coon H, Cullum CM, Griffith JM, Harris JG, Leonard S, Miller C, et al. Schizophrenia and nicotinic receptors. Harv Rev Psychiatry. 1994 Nov-Dec; 2(4):179-92.
Score: 0.023
-
Freedman R, Adler LE, Gerhardt GA, Waldo M, Baker N, Rose GM, Drebing C, Nagamoto H, Bickford-Wimer P, Franks R. Neurobiological studies of sensory gating in schizophrenia. Schizophr Bull. 1987; 13(4):669-78.
Score: 0.013
-
Braff DL, Freedman R, Schork NJ, Gottesman II. Deconstructing schizophrenia: an overview of the use of endophenotypes in order to understand a complex disorder. Schizophr Bull. 2007 Jan; 33(1):21-32.
Score: 0.013
-
Koike K, Hashimoto K, Takai N, Shimizu E, Komatsu N, Watanabe H, Nakazato M, Okamura N, Stevens KE, Freedman R, Iyo M. Tropisetron improves deficits in auditory P50 suppression in schizophrenia. Schizophr Res. 2005 Jul 01; 76(1):67-72.
Score: 0.012
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|